Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.54 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.54 |
| ▸ | FPR2 | P25090 | 1/20 | 0.53 |
| ▸ | CAPN1 | P07384 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.48 |
| ▸ | PPARG | P37231 | 1/20 | 0.48 |
| ▸ | PPARA | Q07869 | 1/20 | 0.48 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.47 |
| ▸ | MMP2 | P08253 | 1/20 | 0.47 |
| ▸ | MMP9 | P14780 | 1/20 | 0.47 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.46 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.46 |
| ▸ | GPR139 | Q6DWJ6 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL428265 | 1.00 | ALDH1A1 (0.54) | ALDH1A1ALOX15FPR2CAPN1KMT2A | |
| SCHEMBL1702385 | 0.87 | FPR2 (0.55) | ALDH1A1ALOX15FPR2KMT2APPARG | |
| SCHEMBL1395877 | 0.84 | FPR2 (0.67) | ALDH1A1ALOX15FPR2KMT2APPARG | |
| SCHEMBL1702272 | 0.83 | PPARG (0.47) | ALDH1A1ALOX15PPARGPPARAKEAP1 | |
| SCHEMBL5080118 | 0.82 | CAPN1 (0.40) | ALDH1A1ALOX15FPR2CAPN1KMT2A | |
| SCHEMBL5215651 | 0.78 | ALDH1A1 (0.67) | ALDH1A1ALOX15FPR2KMT2AGAA | |
| SCHEMBL7390734 | 0.78 | ALDH1A1 (0.67) | ALDH1A1ALOX15FPR2KMT2AGAA | |
| SCHEMBL2003954 | 0.78 | ITGA4 (0.41) | ALDH1A1ALOX15FPR2CAPN1KMT2A | |
| SCHEMBL157547 | 0.76 | MME (0.61) | NPSR1MMP2MMP9 | |
| SCHEMBL20232564 | 0.76 | HSD17B10 (0.46) | POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1773877-B1 | HUMAN GLUCAGON-LIKE-PEPTIDE-1 MODULATORS AND THEIR USE IN THE TREATMENT OF DIABETES AND RELATED CONDITIONS | BRISTOL MYERS SQUIBB CO (US) | 2010-03-17 | — | — | EP | disclosed |
| US-20100022457-A1 | Sustained release glp-1 receptor modulators | BRISTOL-MYERS SQUIBB COMPANY | 2010-01-28 | — | — | US | disclosed |
| US-7534763-B2 | Sustained release GLP-1 receptor modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-05-19 | — | — | US | disclosed |
| EP-2021014-A1 | SUSTAINED RELEASE GLP-1 RECEPTOR MODULATORS | Brystol-Myers Squibb Company (US) | 2009-02-11 | — | — | EP | disclosed |
| US-20080242593-A1 | HUMAN GLUCAGON-LIKE-PEPTIDE-1 MODULATORS AND THEIR USE IN THE TREATMENT OF DIABETES AND RELATED CONDITIONS | BRISTOL-MYERS SQUIBB COMPANY | 2008-10-02 | — | — | US | disclosed |
| US-7417028-B2 | Human glucagon-like-peptide-1 modulators and their use in treatment of diabetes and related conditions | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-08-26 | — | — | US | disclosed |
| WO-2007139589-A1 | SUSTAINED RELEASE GLP-1 RECEPTOR MODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-12-06 | — | — | WO | disclosed |
| US-20070099835-A1 | Sustained release GLP-1 receptor modulators | BRISTOL-MYERS SQUIBB COMPANY | 2007-05-03 | — | — | US | disclosed |
| EP-1773877-A1 | HUMAN GLUCAGON-LIKE-PEPTIDE-1 MODULATORS AND THEIR USE IN THE TREATMENT OF DIABETES AND RELATED CONDITIONS | Bristol-Myers Squibb Company (US) | 2007-04-18 | — | — | EP | disclosed |
| US-20060287242-A1 | Human glucagon-like-peptide-1 modulators and their use in treatment of diabetes and related conditions | BRISTOL-MYERS SQUIBB COMPANY | 2006-12-21 | — | — | US | disclosed |
| WO-2006014287-A1 | HUMAN GLUCAGON-LIKE-PEPTIDE-1 MODULATORS AND THEIR USE IN THE TREATMENT OF DIABETES AND RELATED CONDITIONS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-02-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060287242-A1 | Human glucagon-like-peptide-1 modulators and their use in treatment of diabetes and related conditions | GLP1R, GIPR, IAPP | ALDH1A1 4630/4885ALOX15 2813/4885FPR2 588/4885 |
| US-20080242593-A1 | HUMAN GLUCAGON-LIKE-PEPTIDE-1 MODULATORS AND THEIR USE IN THE TREATMENT OF DIABETES AND RELATED CONDITIONS | GLP1R, GIPR, IAPP | ALDH1A1 4722/4885ALOX15 2620/4885FPR2 445/4885 |
| US-20100022457-A1 | Sustained release glp-1 receptor modulators | GLP1R, GIPR, GRPR | ALDH1A1 3692/4885ALOX15 3125/4885FPR2 1032/4885 |
| US-20070099835-A1 | Sustained release GLP-1 receptor modulators | GLP1R, GIPR, GRPR | ALDH1A1 3692/4885ALOX15 3125/4885FPR2 1032/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.